CDR132L Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for CDR132L comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Heart Failure. Most recent publication: The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial., Nat Med, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Täubel J, Hauke W, Rump S, et al. · Eur Heart J · 2021
    PubMed: PMID 33245749 · NCT04045405 · Heart Failure
  2. Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.
    Huang CK, Kafert-Kasting S, Thum T, et al. · Circ Res · 2020
    PubMed: PMID 32105576 · NCT04045405 · Heart Failure
  3. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.
    Bauersachs J, Solomon SD, Anker SD, et al. · Nat Med · 2026
    PubMed: PMID 42108271 · NCT05350969 (HF-REVERT) · Heart Failure

Publications by year

2020–2026: 3 publications.

2020
1
2021
1
2026
1

Publications by indication

Heart Failure (3)

  • The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.
    Nat Med · 2026 · PMID 42108271 · NCT05350969
  • Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Eur Heart J · 2021 · PMID 33245749 · NCT04045405
  • Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.
    Circ Res · 2020 · PMID 32105576 · NCT04045405

Publications by journal

  • Eur Heart J1 paper
  • Circ Res1 paper
  • Nat Med1 paper

All CDR132L publications (3)

2026 (1 paper)

  1. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.
    Bauersachs J, Solomon SD, Anker SD, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 42108271 · NCT05350969 (HF-REVERT) · Heart Failure

2021 (1 paper)

  1. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Täubel J, Hauke W, Rump S, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 33245749 · NCT04045405 · Heart Failure

2020 (1 paper)

  1. Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.
    Huang CK, Kafert-Kasting S, Thum T, et al. · Circ Res · 2020 · Derived
    PubMed: PMID 32105576 · NCT04045405 · Heart Failure

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 26 May 2026 18:14:50 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).